It has already been demonstrated that the class IIA HDAC inhibitor BML210 inhibits cell growth of AML cell lines by promoting apoptosis and cell-cycle arrest in a dose- and time-dependent manner [54,60]. Here, HDAC9 is linked to acute myeloid leukemia.